title: Bowel perforation after radiotherapy in a patient receiving sorafenib.
authors.affiliation: Department of Experimental Oncology, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: Natascha A J B
authors.initials: NA
authors.lastname: Peters
authors.forename: Dick J
authors.initials: DJ
authors.lastname: Richel
authors.forename: Joost J C
authors.initials: JJ
authors.lastname: Verhoeff
authors.forename: Lukas J A
authors.initials: LJ
authors.lastname: Stalpers
mesh_terms: D000970:Antineoplastic Agents; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced / Q000209:etiology*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D011832:Radiation Injuries / Q000209:etiology*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib